Older data but interesting ..MS summary, page-25

Sammy,

Aside from Sarepta's sketchy FDA approval - without real efficacy data - one other big criticism about Exondys51 is it only treats 13% of boys.

Even with Gene Therapy, we see both Pfizer and Sarepta exclude boys with certain mutations from their program.

Taking the emotion away - looking from the outside - one can see why Sarepta might want to partner with ANP.

...access to 100% of DMD population - USA only - also secure ATL1102 for LGMD too.

$250m per indication + equity position.

Makes perfect sense.
.